{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:45:25Z","timestamp":1782139525126,"version":"3.54.5"},"reference-count":42,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Trimetazidine has been reported to benefit patients with heart failure (HF) and angina. The impact of trimetazidine on non-ischemic HF remains unclear. We reviewed clinical trials to investigate whether trimetazidine could improve exercise endurance, life quality, and heart function in non-ischemic HF patients. We searched the Cochrane Central Register of Controlled Trials, EMBASE, PubMed, and Web of science for randomized clinical trials published before April 30th, 2020; Studies limited to patients with non-ischemic HF, aged \u226518 years, comparing trimetazidine with conventional therapy with\/without placebo. Outcome measurements included primary outcomes (6 minutes walking test (6-MWT)) and secondary outcomes (life quality scores, echocardiography parameters, biomarker, peak oxygen consumption). The follow-up period was longer than three months. This study was registered with international prospective register of systematic reviews (PROSPERO) (CRD42020182982). Six studies with 310 cases were included in this research. Trimetazidine significantly improved 6-MWT (weighted mean difference (WMD) = 48.51 m, 95% confidence interval (CI) [29.41, 67.61], p &lt; 0.0001, I2 = 0%), left ventricle ejection fraction (LVEF) (WMD = 3.09%, 95% CI [1.09, 5.01], p = 0.002, I2 = 0%) at 3 months, and LVEF (WMD = 6.09%, 95% CI [3.76, 8.42], p &lt; 0.0001, I2 = 12%) at 6 months. Furthermore, it reduced peak oxygen consumption (WMD = \u20132.24 mL\/kg per minute, 95% CI [\u20134.09, \u20130.93], p = 0.02). This meta-analysis suggested that trimetazidine might be an effective strategy for improving exercise endurance and cardiac function in patients with non-ischemic HF.<\/jats:p>","DOI":"10.31083\/j.rcm2204149","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:04:36Z","timestamp":1640225076000},"source":"Crossref","is-referenced-by-count":8,"title":["The efficacy of trimetazidine in non-ischemic heart failure patients: a meta-analysis of randomized controlled trials"],"prefix":"10.31083","volume":"22","author":[{"given":"Chengchen","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, 310009 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunna","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, 310009 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"He","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, 310009 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiang","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, 310009 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology. 2014; 63: 1123\u20131133.","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE and Colvin MM. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. 2017; 6: 776\u2013803.","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC: Heart Failure. 2017; 5: 471\u2013482.","DOI":"10.1016\/j.jchf.2017.04.013"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Song J, Chen L, Chen X, Ren J, Zhang N, Tirasawasdichai T, et al. Elevated plasma \u03b2-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. Science Translational Medicine. 2020; 12: eaay8329.","DOI":"10.1126\/scitranslmed.aay8329"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Voros G, Ector J, Garweg C, Droogne W, Van Cleemput J, Peersman N, et al. Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling. Circulation. Heart Failure. 2018; 11: e004953.","DOI":"10.1161\/CIRCHEARTFAILURE.118.004953"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016; 133: 706\u2013716.","DOI":"10.1161\/CIRCULATIONAHA.115.017545"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Nemutlu E, Zhang S, Xu Y, Terzic A, Zhong L, Dzeja PD, et al. Cardiac resynchronization therapy induces adaptive metabolic transitions in the metabolomic profile of heart failure. Journal of Cardiac Failure. 2015; 21: 460\u2013469.","DOI":"10.1016\/j.cardfail.2015.04.005"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992; 86: 1810\u20131818.","DOI":"10.1161\/01.CIR.86.6.1810"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Grajek S, Michalak M. The Effect of Trimetazidine Added to Pharmacological Treatment on all-Cause Mortality in Patients with Systolic Heart Failure. Cardiology. 2015; 131: 22\u201329.","DOI":"10.1159\/000375288"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. International Journal of Cardiology. 2013; 163: 320\u2013325.","DOI":"10.1016\/j.ijcard.2012.09.123"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011; 97: 278\u2013286.","DOI":"10.1136\/hrt.2010.208751"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. Journal of the American College of Cardiology. 2006; 48: 992\u2013998.","DOI":"10.1016\/j.jacc.2006.03.060"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"MacInnes A, Fairman DA, Binding P, Rhodes JA, Wyatt MJ, Phelan A, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circulation Research. 2003; 93: e26\u2013e32.","DOI":"10.1161\/01.RES.0000086943.72932.71"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E and Funck-Brentano C. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020; 3: 407\u2013477.","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients with Nonobstructive Hypertrophic Cardiomyopathy: A randomized clinical trial. JAMA Cardiology. 2019; 4: 230.","DOI":"10.1001\/jamacardio.2018.4847"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Yuanhong L, Chunying L, Hongwen F, Lie L, Dongli C and Silin C. The cardioprotective effects of trimetazidine in dilated cardiomyopathy patients with left bundle branch block. Journal of the American College of Cardiology. 2017; 16: C128\u2013C129.","DOI":"10.1016\/j.jacc.2017.07.459"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Jatain S, Kapoor A, Sinha A, Khanna R, Kumar S, Garg N, et al. Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine. Indian Heart Journal. 2017; 68: 803\u2013808.","DOI":"10.1016\/j.ihj.2016.04.023"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Winter JL, Castro PF, Quintana JC, Altamirano R, Enriquez A, Verdejo HE, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. Journal of Cardiac Failure. 2014; 20: 149\u2013154.","DOI":"10.1016\/j.cardfail.2014.01.004"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Tuunanen H, Engblom E, Naum A, N\u00e5gren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008; 118: 1250\u20131258.","DOI":"10.1161\/CIRCULATIONAHA.108.778019"},{"key":"ref21","unstructured":"Ma Q, Xie Y, Zhang S. Effects of trimetazidine on serum oxygen free radicals in congestive heart failure. Hunan Yi Ke Da Xue Xue Bao. 2003; 27: 527\u2013529. (In Chinese)"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Tarsilla M. Cochrane handbook for systematic reviews of interventions. Journal of Multidisciplinary Evaluation. 2010; 14: 142\u2013148.","DOI":"10.56645\/jmde.v6i14.284"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine. 2009; 7: e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional Use of Trimetazidine in Patients with Chronic Heart Failure: A meta-analysis. Journal of the American College of Cardiology. 2012; 59: 913\u2013922.","DOI":"10.1016\/j.jacc.2011.11.027"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wen J, Ma X, Zhang L, Lu X, Yang Y, Wang J, et al. Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis. Medicine. 2018; 97: e13580.","DOI":"10.1097\/MD.0000000000013580"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circulation Research. 2003; 93: e33\u2013e37.","DOI":"10.1161\/01.RES.0000086964.07404.A5"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circulation Research. 2000; 86: 580\u2013588.","DOI":"10.1161\/01.RES.86.5.580"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovascular Research. 2010; 88: 150\u2013158.","DOI":"10.1093\/cvr\/cvq181"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wu Q, Qi B, Liu Y, Cheng B, Liu L, Li Y, et al. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt\/eNOS signaling pathways. European Journal of Pharmacology. 2013; 707: 87\u201394.","DOI":"10.1016\/j.ejphar.2013.03.027"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Dehina L, Vaillant F, Tabib A, Bui-Xuan B, Chevalier P, Dizerens N, et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2013; 386: 205\u2013215.","DOI":"10.1007\/s00210-012-0826-z"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, et al. Trimetazidine protects against cardiac ischemia\/reperfusion injury via effects on cardiac miRNA\u201121 expression, Akt and the Bcl\u20112\/Bax pathway. Molecular Medicine Reports. 2016; 14: 4216\u20134222.","DOI":"10.3892\/mmr.2016.5773"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Liu Z, Chen J, Huang H, Kuznicki M, Zheng S, Sun W, et al. The protective effect of trimetazidine on myocardial ischemia\/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism: Clinical and Experimental. 2016; 65: 122\u2013130.","DOI":"10.1016\/j.metabol.2015.10.022"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zhang H, Liu M, Zhang Y, Li X. Trimetazidine Attenuates Exhaustive Exercise-Induced Myocardial Injury in Rats via Regulation of the Nrf2\/NF-\u03baB Signaling Pathway. Frontiers in Pharmacology. 2019; 10: 175.","DOI":"10.3389\/fphar.2019.00175"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Yang Y, Li N, Chen T, Zhang C, Liu L, Qi Y, et al. Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK\/mTOR\/autophagy pathway. Pharmaceutical Biology. 2019; 57: 625\u2013631.","DOI":"10.1080\/13880209.2019.1657905"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ferraro E, Pin F, Gorini S, Pontecorvo L, Ferri A, Mollace V, et al. Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. Journal of Cachexia, Sarcopenia and Muscle. 2016; 7: 449\u2013457.","DOI":"10.1002\/jcsm.12097"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Okano M, Sato M, Kageyama S. Lomerizine, trimetazidine and bis-(4-fluorophenyl)-methylpiperazine in human urine after oral administration of lomerizine dihydrochloride: analysis by liquid chromatography-high resolution-tandem mass spectrometry. Drug Testing and Analysis. 2018; 10: 1689\u20131697.","DOI":"10.1002\/dta.2504"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Gunina L, Sheyko V. The World Anti-Doping Agency\u2019s position on ergogenic and recovery pharmacological means and the major principles of their legal usage by athletes. Sporto Mokslas. 2018; 1: 24\u201330.","DOI":"10.15823\/sm.2018.4"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Jarek A, W\u00f3jtowicz M, Kwiatkowska D, Kita M, Turek-Lepa E, Chajewska K, et al. The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration. Drug Testing and Analysis. 2014; 6: 1191\u20131196.","DOI":"10.1002\/dta.1755"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Dy A, Limjoco L and Jamora R. Trimetazidine-Induced parkinsonism: A systematic review. Frontiers in Neurology. 2020; 11: 44.","DOI":"10.3389\/fneur.2020.00044"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Szwed H. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). European Heart Journal. 2001; 22: 2267\u20132274.","DOI":"10.1053\/euhj.2001.2896"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Pascale C, Fornengo P, Epifani G, Bosio A, Giacometto F. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. Lancet. 2002; 359: 1153\u20131154.","DOI":"10.1016\/S0140-6736(02)08135-7"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"van de Bovenkamp AA, Bakermans AJ, Allaart CP, Nederveen AJ, Kok WEM, van Rossum AC, et al. TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study. Netherlands Heart Journal. 2020; 28: 312\u2013319.","DOI":"10.1007\/s12471-020-01407-z"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:41:39Z","timestamp":1732729299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/4\/10.31083\/j.rcm2204149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["S1530-6550(21)00264-7"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2204149","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"article-number":"1451"}}